New Oral Anticoagulants in the Treatment of Patients with Atrial Fibrillation
Journal: Galician Medical Journal (Vol.21, No. 2)Publication Date: 2014-06-30
Authors : L. V. Serediuk; N. M. Serediuk;
Page : 23-26
Keywords : atrial fibrillation; systemic embolism; stroke; new oral anticoagulants;
Abstract
New oral anticoagulants are important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular atrial fibrillation patients. Recently for prevention and treatment of thromboembolism in atrial fibrillation patients antagonists vitamin K, in particular warfarin were used. However, narrow therapeutic window, the need for lifelong monitoring of coagulation and negative interactions with many food products and pharmaceuticals reduces its use. Besides, long-term use of warfarin and its antagonism against vitamin K, which is the regulator of elimination of calcium from the body, can cause calcification of the coronary arteries and valvular heart. In connection with this new oral anticoagulants: dabigatran, rivaroxaban, apixaban are actively used in modern conditions. Their efficacy and safety is proved in randomized clinical trials: RF-LY, ROCKET -AF, ARISTOTLE.
Other Latest Articles
- Pedagogical Methods for Teaching the Discipline “Medicinal Plants and Phytotherapy” at the Department of Pharmacy of IFNMU
- Analysis of Biometric Studies the Small Defects of Dentition with Secondary Dentoalveolar Deformations
- The Peculiarities of Clinico-Paraclinical Data in Children with Diagnosis of “Subfebrility of Unidentified Genesis”
- The Psychological and Philosophic Aspects of Medical Students’ Self-Improvement
- The Medico-Social Peculiarities of Health Condition of Primary School Pupils
Last modified: 2015-11-25 17:35:05